List of Excipients in Branded Drug PEPCID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CARBOXYMETHYLCELLULOSE SODIUM
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CELLULOSE, MICROCRYSTALLINE
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CITRIC ACID MONOHYDRATE

Generic Drugs Containing PEPCID

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	famotidine	0187-4420	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	famotidine	0187-4420	HYDROXYPROPYL CELLULOSE
Bausch Health US LLC	famotidine	0187-4420	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PEPCID?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYPROPYL CELLULOSE
1	MAGNESIUM STEARATE

Pepcid Excipient Strategy and Commercial Opportunities in Famotidine Products

Last updated: September 24, 2026

Pepcid is a famotidine-based acid-reduction franchise with commercial opportunities concentrated in dosage-form differentiation, taste, rapid disintegration, combination therapy, and premium packaging rather than active-ingredient exclusivity. The principal products are Pepcid AC, Pepcid Maximum Strength, Pepcid Complete, and prescription Pepcid. Famotidine is a mature generic active ingredient, so excipient selection is central to consumer preference, manufacturing cost, product stability, and product-line extension.

What is the Pepcid product and excipient strategy?

Pepcid products use famotidine as an H2-receptor antagonist. The product architecture separates into three commercial platforms:

Product platform	Active ingredients	Primary consumer proposition	Excipient role
Pepcid AC	Famotidine, typically 10 mg or 20 mg	Heartburn prevention and relief	Tablet strength, swallowability, stability, low-cost manufacture
Pepcid Chewables	Famotidine, typically 10 mg	Chewable heartburn relief	Taste masking, mouthfeel, rapid dispersion
Pepcid Complete	Famotidine plus calcium carbonate and magnesium hydroxide	Immediate and longer-duration relief	Antacid suspension, chewability, mineral compatibility, flavor
Prescription Pepcid	Famotidine in oral and injectable presentations	Treatment of acid-related disorders in clinical settings	Dose flexibility, sterility for injection, compatibility and stability

The exact inactive-ingredient profile varies by product, strength, market, and manufacturer. U.S. labeling identifies excipients such as microcrystalline cellulose, starch-based disintegrants, magnesium stearate, colloidal silicon dioxide, film-coating materials, sweeteners, flavors, and colorants in tablet and chewable presentations. Pepcid Complete adds antacid minerals and requires a different excipient system to maintain acceptable taste, texture, dose uniformity, and stability. Product-specific labels are the controlling source for final composition (Kenvue, 2024a; DailyMed, 2024a).

Why excipients matter more for Pepcid than for a new chemical entity

Famotidine has limited differentiation at the molecule level. Most competitive products can match the active ingredient, strength, and basic route of administration. Excipients therefore determine several commercially relevant attributes:

• Speed of tablet breakup and perceived onset.
• Chewable texture and aftertaste.
• Compatibility of famotidine with calcium and magnesium antacids.
• Moisture resistance and shelf stability.
• Tablet size and ease of swallowing.
• Manufacturing yield and compression performance.
• Color, brand recognition, and packaging consistency.
• Suitability for sugar-free, gluten-free, low-sodium, or allergen-conscious claims.

For a mature OTC product, a small improvement in taste or convenience can support a premium price even when the active ingredient is generic.

What formulations are protected by Pepcid’s excipient strategy?

Pepcid’s principal formulation differentiation is concentrated in combination and consumer-use formats rather than a basic famotidine tablet.

Standard immediate-release tablets

Standard Pepcid AC tablets rely on conventional direct-compression or wet-granulation excipients. Microcrystalline cellulose can provide compressibility and tablet structure. Crospovidone, croscarmellose sodium, sodium starch glycolate, or related disintegrants can improve breakup after ingestion. Magnesium stearate supports lubrication but must be controlled because excess lubricant can reduce tablet wetting and dissolution.

The strategic objective is a robust, low-cost tablet with acceptable dissolution and low defect rates. These formulations are technically accessible to generic manufacturers. Their commercial value depends on brand recognition, shelf placement, packaging, and consumer trust more than on complex excipient barriers.

Chewable famotidine products

Chewable tablets require a different formulation strategy. The most important excipient functions are:

1. Sweetness and bitterness control.
2. Low grittiness.
3. Rapid dispersion in the mouth.
4. Adequate hardness during packaging and transport.
5. Controlled friability during chewing.
6. Stable flavor over shelf life.

Famotidine has a bitter pharmaceutical taste. Chewable products therefore create formulation risk around flavor persistence, sweetener degradation, and interactions between flavor oils and tablet components. Sugar alcohols such as sorbitol, mannitol, or xylitol can improve mouthfeel, although they affect compression, hygroscopicity, and gastrointestinal tolerance. Aspartame, sucralose, acesulfame potassium, or other high-intensity sweeteners may reduce tablet mass but require careful flavor balancing.

A generic chewable competitor must match sensory performance, not merely active-ingredient content. This creates a moderate commercial barrier, although it is generally not a strong patent barrier.

Pepcid Complete combination tablets

Pepcid Complete combines famotidine with calcium carbonate and magnesium hydroxide. The formulation delivers rapid antacid neutralization together with longer-duration acid suppression from famotidine. Its commercial differentiation is stronger than that of a standard famotidine tablet because the product combines two pharmacologic mechanisms in a single chewable format.

Excipient priorities include:

• Uniform distribution of mineral antacids and famotidine.
• Control of density differences among active ingredients.
• Prevention of segregation during blending and tableting.
• Adequate hardness without excessive chew resistance.
• Flavor masking for both famotidine bitterness and mineral chalkiness.
• Moisture control.
• Compatibility with calcium carbonate and magnesium hydroxide.
• Consistent neutralizing capacity and dissolution.

Calcium carbonate can create a chalky sensory profile. Magnesium hydroxide can contribute to texture and gastrointestinal effects. The excipient system must produce a smooth, acceptable chew while preserving antacid performance. This is a more difficult formulation target than a conventional film-coated famotidine tablet.

What commercial opportunities exist for Pepcid excipient innovation?

1. Sugar-free and reduced-calorie chewables

Sugar-free chewables can broaden use among consumers who avoid sucrose. Polyols and high-intensity sweeteners can support this positioning, but formulation teams must manage hygroscopicity, cooling effects, laxation risk, and compression behavior.

A sugar-free platform could support:

• Premium chewable products.
• Smaller tablet formats.
• Pediatric or family-oriented positioning where appropriate.
• Multi-pack and travel formats.
• Private-label and retailer-exclusive products.

The commercial opportunity is strongest if taste remains comparable to the branded product. A sugar-free claim without acceptable sensory performance is unlikely to create durable share.

2. Faster-dispersing tablets

Fast-dissolving or orally disintegrating famotidine products could target consumers seeking relief without water. Formulation options include porous compression, taste-masked granules, rapidly wicking excipients, and optimized superdisintegrant systems.

Key development risks include:

• Famotidine bitterness after rapid wetting.
• Tablet friability.
• Moisture sensitivity.
• Packaging cost.
• Dose uniformity at low tablet mass.
• Whether the product has a meaningful consumer-perceived onset advantage over existing Pepcid products.

The strongest commercial positioning would be convenience rather than a therapeutic superiority claim unless supported by clinical data.

3. Improved Pepcid Complete sensory performance

The combination tablet has the clearest excipient-led opportunity. Potential improvements include:

• Lower chalkiness.
• Smoother chew texture.
• Reduced aftertaste.
• Smaller tablet size.
• Better flavor persistence.
• Lower moisture pickup.
• Improved stability under high-temperature storage.

An improved formulation could support a line extension without changing the active ingredients. The principal barrier is execution: the product must preserve antacid performance while improving consumer acceptance.

4. Liquid and suspension products

Famotidine oral suspensions can address pediatric, geriatric, and dysphagia populations. Excipient development would involve suspending agents, wetting agents, buffers, preservatives, sweeteners, flavors, and sedimentation control.

The main technical issues are:

• Chemical stability in aqueous media.
• Uniform dose delivery after shaking.
• Palatability.
• Preservative effectiveness.
• Container compatibility.
• In-use stability.
• Accurate dosing with an oral syringe.

A liquid product would require a clear regulatory and medical-use strategy. It is more relevant to prescription or specialty channels than to the core adult OTC Pepcid franchise.

5. Low-allergen and clean-label positioning

Consumers increasingly examine inactive ingredients. Opportunities include formulations that exclude selected dyes, lactose, gluten-derived excipients, or artificial flavors where technically feasible. These claims must be supported by the actual composition and applicable labeling rules.

The commercial value depends on whether the excluded ingredient is material to the target consumer. Removing a dye may improve appeal among ingredient-sensitive consumers, but it can increase color variability and reduce brand recognition.

6. Private-label and licensing opportunities

Famotidine products are suitable for contract manufacturing, retailer brands, and private-label acid reducers. A formulation owner could license:

• A chewable taste-masking system.
• A sugar-free Pepcid-equivalent platform.
• A famotidine-antacid combination.
• A rapidly disintegrating tablet.
• A stable liquid suspension.
• A low-cost high-throughput tablet process.

The most defensible licensing asset would combine formulation know-how, analytical methods, sensory data, manufacturing validation, and regulatory documentation. An isolated excipient list is easier to design around and has limited licensing value.

What is the FDA regulatory status of Pepcid?

Pepcid is an FDA-authorized famotidine product family. Famotidine is available in prescription and OTC presentations, including products for heartburn prevention and relief. The FDA approved the OTC switch of famotidine products in the 1990s, and current OTC products are marketed under applicable FDA requirements and product-specific labeling (U.S. Food and Drug Administration [FDA], 1995).

Pepcid Complete is regulated as a drug product because it contains active drug ingredients with therapeutic claims. Its labeling must address directions, warnings, age restrictions, drug interactions, and maximum daily use. Combination products also require consistent labeling of each active ingredient and appropriate warnings for antacid use.

What is the Orange Book status of Pepcid?

The Orange Book principally identifies approved prescription drug products and their therapeutic-equivalence information. OTC Pepcid products are not generally analyzed in the same way as prescription products with active Orange Book patents and exclusivity listings. Prescription famotidine products may appear in FDA approval databases, but the commercial OTC franchise does not depend on current Orange Book patent protection.

For excipient-led OTC competition, the relevant regulatory pathway is usually an abbreviated or monograph-based route, depending on product classification, formulation, and current FDA requirements. A manufacturer must establish conformity to the applicable standard, demonstrate product quality, and support any formulation or labeling differences.

When does famotidine lose exclusivity?

Famotidine’s core compound and early product exclusivity expired decades ago. The active ingredient is widely available from generic manufacturers. Current commercial protection therefore comes from brand equity, regulatory approvals, trademarks, formulation know-how, packaging, and any enforceable formulation or method-of-use rights.

A standard famotidine tablet has low patent barriers. Combination chewables and differentiated delivery systems may have stronger formulation positions, but the strength depends on claim scope, prosecution history, enablement, prior art, and design-around options.

How strong is the Pepcid patent estate?

The Pepcid patent estate is commercially stronger as a brand and formulation platform than as a basic active-ingredient estate.

Protection category	Current strategic value	Generic vulnerability
Famotidine composition of matter	Low	Very high
Conventional immediate-release tablet	Low to moderate	High
Chewable taste and texture	Moderate	Moderate
Famotidine-antacid combination	Moderate	Moderate
Orally disintegrating format	Moderate	Moderate
Packaging and trade dress	Moderate	Moderate, subject to trademark limits
Manufacturing know-how	Moderate	Depends on process complexity
Prescription method of use	Low to moderate	High where use claims are narrow

No current conclusion about an enforceable Pepcid formulation patent should be drawn from the brand name alone. Patent review must be conducted by jurisdiction, product, assignee, claim type, and legal status. For commercial planning, the principal risk is usually regulatory and executional rather than Paragraph IV litigation.

What patent litigation and Paragraph IV risks affect Pepcid?

Generic famotidine tablets face limited litigation risk because the active ingredient is long genericized and basic dosage forms are readily reproducible. Risk increases for:

• Famotidine-antacid combinations.
• Distinctive chewable formulations.
• Orally disintegrating tablets.
• Liquid products with unusual stability systems.
• Narrow method-of-use claims.
• Formulations with specific excipient ratios or dissolution profiles.

A Paragraph IV challenge would be relevant only if an approved generic product were seeking to market before expiration of a listed patent. Because OTC Pepcid products are not typically managed through the same Orange Book patent framework as newer prescription products, a standard Paragraph IV strategy is less central than it is for patented prescription drugs.

Which companies are challenging or competing with Pepcid?

Competition comes from three groups:

1. Generic famotidine manufacturers, including suppliers of tablets and chewables.
2. Retailer private-label brands.
3. Alternative acid-reduction products, including proton-pump inhibitors, antacids, alginate products, and other H2 blockers.

The principal commercial competitors are not limited to products with the same active ingredient. Consumers may substitute between famotidine, omeprazole, esomeprazole, calcium carbonate antacids, and alginate-based products depending on desired speed, duration, and frequency of symptoms.

Pepcid’s strongest competitive position is the combination of established brand recognition, broad retail distribution, and multiple dosage forms. Its weaker position is price competition in standard famotidine tablets.

How does Pepcid compare with competing acid-reduction products?

Attribute	Pepcid famotidine	Proton-pump inhibitor	Simple antacid
Typical consumer use	Rapid heartburn prevention or relief	Longer-course acid suppression	Fast short-term neutralization
Formulation opportunity	Chewables, combinations, fast-disintegrating tablets	Delayed-release and enteric systems	Flavor, suspension, chewability
Excipient complexity	Moderate	High, especially for enteric protection	Moderate
Patent leverage today	Limited for basic products	Product-specific and formulation-dependent	Generally low
Main consumer decision	Speed and convenience	Duration and regimen	Immediate neutralization and price

Pepcid Complete competes most directly with combination antacid products because it combines famotidine with calcium carbonate and magnesium hydroxide. Standard Pepcid AC competes with generic famotidine and other H2-receptor antagonists.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate for Pepcid Complete and lower for standard tablets. The main process risks include:

• Segregation of ingredients with different particle sizes and densities.
• Poor flow during high-speed tableting.
• Capping and lamination.
• Flavor loss or migration.
• Moisture-driven degradation.
• Mineral abrasion and tooling wear.
• Inconsistent chewable hardness.
• Cross-contamination control in combination-product facilities.

An effective manufacturing package should include particle-size specifications, blending controls, compression-force ranges, disintegration and dissolution methods, sensory acceptance criteria, and stability data under accelerated and long-term conditions.

Trade-secret protection may be more practical than patent protection for certain excipient ratios, granulation conditions, flavor systems, and process controls. Patent claims can protect a formulation only if they distinguish over prior art and withstand design-around analysis.

What generic launch scenarios exist for Pepcid?

Scenario 1: Low-cost standard tablet

This is the easiest entry path. A generic manufacturer can compete on price and retailer access. The product has limited differentiation and weak barriers.

Scenario 2: Branded generic chewable

A chewable product can command a higher price if taste, tablet size, and packaging approach the branded benchmark. Sensory testing becomes a key launch requirement.

Scenario 3: Combination antacid product

A famotidine-calcium carbonate-magnesium hydroxide product can compete directly with Pepcid Complete. The formulation is more technically demanding, but the consumer proposition is also more differentiated.

Scenario 4: Premium rapid-dissolve product

A fast-dispersing product can target convenience-oriented consumers. The launch requires evidence that the dosage form offers a meaningful user benefit without unacceptable bitterness or packaging cost.

Scenario 5: Retailer-exclusive platform

Retailers can use a contract-manufactured famotidine product to capture margin through private label. The most attractive formats are standard tablets, chewables, and combination products with differentiated packaging.

What are the revenue and commercial exposure considerations?

Revenue exposure is concentrated in OTC retail channels, including mass merchants, pharmacies, grocery stores, e-commerce, and club stores. Exact Pepcid revenue should be assessed from Kenvue segment disclosures because Pepcid is part of a broader self-care portfolio rather than a separately reported public-company segment in most filings.

The highest-value commercial assets are likely:

• Brand recognition.
• Retail distribution.
• Product-family breadth.
• Combination-product differentiation.
• Consumer familiarity with the Pepcid name.
• Repeat purchase for episodic heartburn.
• Shelf and digital-search visibility.

The most exposed products are standard-strength tablets with numerous generic and private-label substitutes. The least vulnerable formats are those with strong sensory performance, convenient dosing, and a clearly communicated combination benefit.

Key Takeaways

• Pepcid’s active ingredient, famotidine, is mature and widely genericized.
• Excipient strategy is most valuable in chewable, combination, fast-dissolving, sugar-free, and liquid formats.
• Pepcid Complete has greater formulation complexity and differentiation than standard Pepcid AC tablets.
• Taste masking, chalkiness control, tablet texture, and moisture stability are the main development priorities.
• Basic famotidine tablets have low patent barriers and high generic vulnerability.
• Formulation know-how, sensory data, manufacturing controls, and packaging can provide practical commercial protection.
• Paragraph IV litigation is less central for OTC Pepcid than for newer prescription products with listed Orange Book patents.
• The strongest commercial opportunities are premium chewables, famotidine-antacid combinations, sugar-free products, and retailer-exclusive formulations.

FAQs

Can a generic manufacturer copy Pepcid’s inactive ingredients?

A manufacturer can generally use comparable excipients, but it cannot assume that copying a branded formulation is sufficient for regulatory approval. The product must meet applicable quality, performance, labeling, and manufacturing requirements. Trade dress and trademark restrictions also apply.

Which Pepcid product has the greatest formulation barrier?

Pepcid Complete has the greatest formulation barrier among the main OTC products because it combines famotidine with calcium carbonate and magnesium hydroxide in a chewable dosage form. Taste, texture, segregation, and stability all require control.

Are excipients in Pepcid patentable?

Specific excipient combinations, ratios, particle sizes, processing conditions, or performance characteristics may be patentable if they are novel and non-obvious. Conventional excipients used in routine tablet manufacture usually provide weak patent positions.

Is Pepcid Complete more defensible than Pepcid AC?

Yes, from a formulation perspective. Pepcid Complete has a more differentiated active-ingredient combination and more demanding sensory and manufacturing requirements. Its legal defensibility still depends on the current patent record and claim scope.

What is the most attractive licensing opportunity in the Pepcid market?

A validated chewable or combination-product platform with strong taste-masking performance, stable shelf life, scalable manufacturing, and regulatory documentation is more attractive than a basic famotidine tablet formulation.

References

1. DailyMed. (2024a). PEPCID AC and PEPCID COMPLETE product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. Kenvue. (2024a). Pepcid product information and consumer labeling. https://www.pepcid.com/

3. U.S. Food and Drug Administration. (1995). FDA approves over-the-counter marketing of famotidine for heartburn. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drug database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. 44th ed. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

6. U.S. Food and Drug Administration. (2024c). Over-the-counter monograph system and OTC drug requirements. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs